Now Available: Final Rule for FDAAA 801 and NIH Policy on Clinical Trial Reporting

Phase 2 Study of Velusetrag in Diabetic or Idiopathic Gastroparesis

This study has been completed.
Alfa Wassermann S.p.A.
Information provided by (Responsible Party):
Theravance Biopharma R & D, Inc. Identifier:
First received: October 29, 2012
Last updated: May 11, 2015
Last verified: May 2015
No Study Results Posted on for this Study
  Study Status: This study has been completed.
  Study Completion Date: February 2014
  Primary Completion Date: December 2013 (Final data collection date for primary outcome measure)